Vanguard Group Inc. Has $52.32 Million Holdings in CorMedix Inc $CRMD

Vanguard Group Inc. increased its position in shares of CorMedix Inc (NASDAQ:CRMD) by 13.1% during the fourth quarter, Holdings Channel reports. The fund owned 4,499,010 shares of the company’s stock after acquiring an additional 521,352 shares during the quarter. Vanguard Group Inc. owned approximately 0.06% of CorMedix worth $52,323,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Financial Management Professionals Inc. acquired a new stake in shares of CorMedix during the fourth quarter valued at approximately $25,000. Comerica Bank raised its holdings in shares of CorMedix by 454.6% during the third quarter. Comerica Bank now owns 2,690 shares of the company’s stock valued at $31,000 after acquiring an additional 2,205 shares during the period. Canada Pension Plan Investment Board acquired a new stake in shares of CorMedix during the second quarter valued at approximately $42,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of CorMedix by 666.6% during the third quarter. Caitong International Asset Management Co. Ltd now owns 4,385 shares of the company’s stock valued at $51,000 after acquiring an additional 3,813 shares during the period. Finally, State of Alaska Department of Revenue acquired a new stake in shares of CorMedix during the third quarter valued at approximately $54,000. Institutional investors and hedge funds own 34.18% of the company’s stock.

More CorMedix News

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: CorMedix beat Q1 estimates, with DefenCath driving triple-digit revenue growth and supporting a higher full-year outlook. CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
• Positive Sentiment: The company raised FY2026 revenue guidance to $325 million-$345 million, above Wall Street expectations, signaling management confidence in continued demand and execution. CorMedix Q1 2026 Financial Results and Business Update
• Positive Sentiment: CorMedix announced upcoming investor conference participation, which could help keep attention on the name and provide more updates on growth strategy. CorMedix to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Analyst commentary and earnings-call recaps are reinforcing the same message: strong quarterly performance, improving profitability, and continued momentum in the core product. Analysts Offer Insights on Healthcare Companies: Immatics and CorMedix
• Neutral Sentiment: Unusually heavy options activity suggests traders expect continued volatility around the earnings-driven move in CRMD.

CorMedix Trading Down 4.8%

CorMedix stock opened at $7.55 on Friday. The company’s fifty day simple moving average is $7.10 and its 200-day simple moving average is $8.66. The company has a quick ratio of 1.94, a current ratio of 2.11 and a debt-to-equity ratio of 0.36. CorMedix Inc has a 12 month low of $6.13 and a 12 month high of $17.43. The stock has a market cap of $592.24 million, a P/E ratio of 3.54 and a beta of 1.46.

CorMedix (NASDAQ:CRMD) last posted its quarterly earnings results on Thursday, May 14th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.35 by $0.08. CorMedix had a net margin of 45.25% and a return on equity of 49.12%. The business had revenue of $127.43 million for the quarter, compared to analysts’ expectations of $104.96 million. During the same period in the previous year, the company posted $0.30 EPS. CorMedix’s revenue was up 226.1% on a year-over-year basis. As a group, sell-side analysts forecast that CorMedix Inc will post 0.44 EPS for the current fiscal year.

CorMedix declared that its board has approved a stock repurchase plan on Monday, February 2nd that authorizes the company to buyback $75.00 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 12.3% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Leerink Partners boosted their price target on shares of CorMedix from $13.00 to $14.00 and gave the company an “outperform” rating in a report on Tuesday, April 28th. Royal Bank Of Canada restated an “outperform” rating and set a $14.00 price target (up from $13.00) on shares of CorMedix in a report on Tuesday, April 28th. Needham & Company LLC boosted their price target on shares of CorMedix from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, April 27th. HC Wainwright cut their price target on shares of CorMedix from $18.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Finally, Citizens Jmp restated a “market outperform” rating and set a $19.00 price target on shares of CorMedix in a report on Tuesday, April 28th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

About CorMedix

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.